187 related articles for article (PubMed ID: 37246090)
1. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma.
Braun DA; Chakraborty AA
Hematol Oncol Clin North Am; 2023 Oct; 37(5):827-840. PubMed ID: 37246090
[TBL] [Abstract][Full Text] [Related]
2. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
[TBL] [Abstract][Full Text] [Related]
3. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract][Full Text] [Related]
4. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM; Labaki C; Jammihal TR; Xie W; Sun M; Shah V; Saad E; Kane MH; Kashima S; Sadak K; El Zarif T; Poduval D; Motzer RJ; Powles T; Rini BI; Albiges L; Pal SK; McGregor BA; McKay RR; Signoretti S; Van Allen EM; Shukla SA; Choueiri TK; Braun DA
Cancer Cell; 2024 May; 42(5):732-735. PubMed ID: 38579722
[TBL] [Abstract][Full Text] [Related]
5. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma.
Patel HV; Srivastava A; Srinivasan R; Singer EA
Curr Opin Oncol; 2021 May; 33(3):212-220. PubMed ID: 33818540
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
7. The immunology of renal cell carcinoma.
Díaz-Montero CM; Rini BI; Finke JH
Nat Rev Nephrol; 2020 Dec; 16(12):721-735. PubMed ID: 32733094
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
10. The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.
Hu SL; Chang A; Perazella MA; Okusa MD; Jaimes EA; Weiss RH;
J Am Soc Nephrol; 2016 Aug; 27(8):2227-37. PubMed ID: 26961346
[TBL] [Abstract][Full Text] [Related]
11. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
12. Towards individualized therapy for metastatic renal cell carcinoma.
Kotecha RR; Motzer RJ; Voss MH
Nat Rev Clin Oncol; 2019 Oct; 16(10):621-633. PubMed ID: 30992569
[TBL] [Abstract][Full Text] [Related]
13. PD1/PD-L1 therapy in metastatic renal cell carcinoma.
Bruchbacher A; Lemberger U; Hassler MR; Fajkovic H; Schmidinger M
Curr Opin Urol; 2020 Jul; 30(4):534-541. PubMed ID: 32453005
[TBL] [Abstract][Full Text] [Related]
14. Update on the biology and management of renal cell carcinoma.
Dutcher JP
J Investig Med; 2019 Jan; 67(1):1-10. PubMed ID: 30455223
[TBL] [Abstract][Full Text] [Related]
15. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
[TBL] [Abstract][Full Text] [Related]
16. Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy.
Ali M; Eid M; Saliby RM; Choi S; McKay RR; Siva S; Braun DA; Chen YW
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438658. PubMed ID: 38875505
[TBL] [Abstract][Full Text] [Related]
17. Molecular-based therapies for renal cell carcinoma.
Zisman A; Pantuck AJ; Belldegrun AS
Curr Urol Rep; 2001 Feb; 2(1):55-61. PubMed ID: 12084296
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
19. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.
Salgia NJ; Zengin ZB; Pal SK; Dizman N
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438642. PubMed ID: 38776514
[TBL] [Abstract][Full Text] [Related]
20. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
